Theoretical and Observed Mechanisms of Diesel Exhaust Particles in Promoting Asthma
Yuan Gao,Yan Zhou,Xinjia Zhou,Rui Zheng,Peifang Wei
DOI: https://doi.org/10.1097/cm9.0000000000002592
IF: 6.133
2023-01-01
Chinese Medical Journal
Abstract:To the Editor: Diesel exhaust particles (DEPs) promote airway inflammation in asthma, but the mechanisms by which DEPs influence the onset and aggravation of asthma are complex. Standard DEPs have been used in many toxicological studies about DEPs and asthma. However, recent studies have shown that standard DEPs are unsuitable representatives of traffic-related emissions. The effects of regenerated DEPs and real-world DEPs on asthma have not been fully studied and more researches are urgently needed. Exposure to DEPs has been associated with an increased onset of asthma and exacerbation of pre-existing asthma. The composition and amount of organic compounds in DEPs vary depending on various factors, such as fuel type, combustion temperature, engine load, drive cycle, and combustion technology. Standard DEPs, such as standard reference materials (e.g., SRM 2975), have been obtained from commercially generated sources and used in many toxicological studies about DEPs and asthma. However, recent studies have shown that standard DEPs lack several high-molecular-weight carcinogenic polycyclic aromatic hydrocarbons (PAHs) and toxic secondary organic aerosols compared with real-world DEPs. Thus, various governments and industries worldwide have developed and implemented various post-combustion aftertreatment technologies to catalyze the mitigation of specific toxic by-products. However, regenerated DEPs treated with diesel particulate filters or urea-based selective catalytic reduction systems may cause acute lung inflammation. In addition, compared with DEPs without post-combustion aftertreatment, regenerated DEPs may have a stronger effect on promoting inflammation. However, the effects of regenerated and real-world DEPs on asthma development remain unclear. Specifically, the mechanisms by which different types of DEPs promote the onset and aggravation of asthma are not fully understood. Thus, we aimed to retrospectively analyze the pathogenesis of asthma caused by different DEPs via the direct receptor pathway, barrier dysfunction, dendritic cell maturation, adaptive immunity, and epigenetic modifications. We searched the MEDLINE, Web of Science, and Science Direct databases for articles published between January 1998 and July 2022 by using the key words “DEPs”, “standard reference material”, “regenerated DEPs”, “real-world DEPs,” and “asthma” and obtained 64 articles. This article provides updated knowledge and understanding of the different mechanisms by which DEPs trigger asthma development. This paper may serve as a basis for further studies identifying the DEP components involved in post-combustion aftertreatment and the organic components triggering asthma. DEPs and Direct Receptor Pathways: DEPs cause oxidative stress and airway inflammation through different receptor pathways. Standard DEPs dose-dependently increase the production of interleukin (IL)-17A in primary bronchial epithelial cells. They also increase reactive oxygen species (ROS) production and IL-17A expression in airway epithelial cells through the ROS/nuclear factor-κB pathway.[1] The transient receptor potential (TRP) channels are transmembrane channels that regulate influxes of cations (such as Ca2+). The expression of vanillic acid 1 is increased in the TRP channel of the bronchial epithelia of patients with severe asthma. Different combustion particles (such as DEPs) induce Ca2+ influx in lung epithelial cells and sensory neurons, which is mediated by transient receptor potential A1 (TRPA1), transient receptor potential vanilloid type 1 (TRPV1), transient receptor potential vanilloid type 4 (TRPV4), and transient receptor potential cation channel subfamily M member 8 (TRPM8). PAHs, the main component of SRM 2975, are implicated in the activation of aromatic hydrocarbon receptors, and the subsequent generation of mitochondrial ROS can activate TRPA1 expression in the lung C-fibers of mice and cause airway hyperresponsiveness and respiratory symptoms.[2] Different DEPs differ in toxicity levels because they vary in chemical compositions and activate TRPA1 differently, and research found regenerated DEPs can increase IL-8 messenger RNA (mRNA) expression more significantly than SRM 2975 and “black smoker DEPs.”[3] Soluble organic extracts of DEPs activate protease-activated receptor 2 through protease, which then activates Ca2+ influx through the TRPV4 channel. In addition, PAHs regulate IL-8/C-X-C motif chemokine ligand 8 in bronchial epithelial cells by activating β2 adrenergic receptor (β2AR) and calcium signaling. Therefore, β2AR can be another molecular target of organic DEPs components. There is also direct interaction between DEPs and intracellular molecular targets, such as the aryl hydrocarbon receptor (AHR). PAHs and other organic chemicals in DEPs can bind to AHR, which consequently upregulates the expression of genes related to inflammation and heterologous metabolism. Exposure of bronchial epithelial cells to standard DEPs upregulates the expression of IL-25, IL-33, and thymic stromal lymphopoietin (TSLP) by increasing AHR/aryl hydrocarbon receptor nuclear translocator (ARNT) binding to IL-25, IL-33, and TSLP promoters.[4] DEPs activate AHR, which then mediates the upregulation of IL-25, IL-33, TSLP, and T helper 2 cell (Th2) activation. This mechanism directly links DEP exposure to severe allergic asthma. AHR is clearly a highly sensitive target for the dioxin-like components of PAHs and DEPs, and other combustion-derived particulates, and may therefore have important implications in immunotoxicity. Barrier Dysfunction and Dendritic Cell (DC) Maturation Caused by DEPs: Defects in epithelial barrier function are a characteristic of airway inflammation in patients with asthma. Epithelial dysfunction may promote innate and adaptive immune responses by changing the epithelial structure or facilitating the intraepithelial DC presenting of luminal allergen. SRM 2975 can modulate and degrade zonula occludens 1 (ZO-1), tricellulin, and occludin; increase the conductivity of the alveoli across the epithelium; and cause epithelial barrier dysfunction. Exposure of human bronchial epithelial cells to DEPs induces DC maturation and functionality. Mechanistically, it upregulates the expression of OX40 ligands and Jagged-1 ligands in myeloid DCs through TSLP, thereby increasing Th2 immunity. DEPs and Adaptive Immunity: DEPs can act as adjuvants to allergens, increasing sensitization by enhancing allergic reactions and producing allergic and refractory asthma phenotypes. Th2 immunity: Allergic asthma is a Th2 disease characterized by elevated levels of eosinophils and Th2 cytokines (such as IL-4, IL-5, and IL-13). Compared with exposure to ovalbumin (OVA) alone, repeated exposure to DEPs and OVA amplifies allergen-specific Th2 responses, resulting in higher levels of IL-4 and IL-5 in the lung. Regenerated DEPs can also be used as adjuvants to enhance dust mite allergen sensitization, airway hyperresponsiveness, and airway remodeling and activate Th2 polarization. Besides, exposure to SRM 2975 and house dust mites (HDMs) significantly enhances allergic airway inflammation, eosinophilia, goblet cell metaplasia, type-2 innate lymphoid cells (ILC2) accumulation, type 2 cytokine production, and airway hyperresponsiveness.[5] As a result of exposure to SRM 2975 and HDMs, IL-33/ suppression of tumorigenicity 2 receptor (ST2) expression is elevated in the lungs, and IL-33/ST2 pathway contributes to the DEP-enhanced onset of allergic airway inflammation.[6] Th2/Th17 immunity: Severe asthma is usually characterized by a mixed Th2 and Th17 response. Simultaneous exposure to standard DEPs and HDMs exacerbates allergic sensitization and induces severe key features of asthma, including Th7 and Th2/Th17 effector T cells. The offspring of mice prenatally exposed to DEPs are allergic to OVA and have elevated levels of lung and systemic Th2 and Th17 cytokines associated with an increase in aryl hydrocarbon receptor and oxidative stress-regulated gene transcription.[7] Co-exposure to standard DEPs and HDMs promotes the accumulation of Th2/Th17 coproducer cells and Th17 cells in the lungs of exposed adult mice, resulting in persistent existence of Th2/Th17 CD127 memory cells in the lungs, spleen, and lymph nodes of both the adult and newborn mice.[8] This enhances secondary allergen recall response and promotes the development of allergic asthma, thereby increasing asthma susceptibility in offspring. The IL-33/ST2 pathway contributes to the DEP (U.S. Environmental Protection Agency laboratories) and HDM co-exposure-mediated increases in allergic Th2 inflammation and airway hyperresponsiveness in a mouse model of severe steroid-resistant asthma via the accumulation of pathogenic IL5+ IL17A+ CD4+ effector T cells.[9] DEPs and Epigenetic Modification: Asthma develops as a result of a complex interaction between environmental exposure and individual genetic susceptibility. Exposure of mice to environmental particles during pregnancy increases the risk of asthma in F1 to F3 offspring. Inhalation of diesel engine exhausts or allergens can alter DNA methylation in the human bronchial epithelium. Furthermore, pre-pregnancy DEPs exposure can promote asthma in offspring through NK cell-derived granzyme B.[10] NK cell-derived granzyme B induces IL-25 expression in airway epithelial cells to promote asthma, and the NK cell/airway epithelial axis plays an important role in the transmission of DEPs-triggered asthma susceptibility from the mother to her offspring.[10] In summary, DEPs promote asthma development through various mechanisms [Figure 1]. Standard DEPs have been used to explore the various triggering mechanisms of DEPs. Understanding the comprehensive effects of regenerated and real-world DEPs on asthma is important to elucidate the mechanisms by which DEPs induce asthma. However, further studies are warranted to identify the DEP components involved in post-combustion aftertreatment triggering asthma.Figure 1: Mechanisms by which DEPs promote asthma. (A) Diesel exhaust particles (DEPs) and direct receptor pathway. (B) DEPs act as an adjuvant to promote asthma. AhR: Aryl hydrocarbon receptor; ARNT: Aryl hydrocarbon receptor nuclear translocator; DEPs: Diesel exhaust particles; IL: Interleukin; ILC2: Type-2 innate lymphoid cells; mDCs: Myeloid dendritic cells; NF-κB: Nuclear factor-κB; NK: Natural killer cell; OVA: Ovalbumin; PAR-2: Protease-activated receptor 2; ROS: Reactive oxygen species; ST2: Suppression of tumorigenicity 2 receptor; Th2: T helper 2 cell; Th17: T helper 17 cell; TRPA1: Transient receptor potential A1; TRPV1: Transient receptor potential vanilloid type 1; TRPV4: transient receptor potential vanilloid type 4; TSLP: Thymic stromal lymphopoietin; ZO-1: Zonula occludens 1.Funding This study was supported by grants from the National Natural Science Foundation of China (No. 82100020), 345 Talent Project of Shengjing Hospital, and Science and Technology Projects in Liaoning Province (No. 2020JH2/10300125). Conflicts of interest None.